Search published articles


Showing 4 results for Acne
Prevalence of truncal acne in high school students: a community based study
S.z.ghodsi, Z.n. Hatmi, A. Nikfarjam, F. Safar, P.noormohammadpoor, M. Asheghan,
Volume 64, Issue 3 (5-2006)
Abstract

Background: Acne is one of the most common skin diseases especially in adolescence. Different studies have reported unequal rates of facial acne prevalence in different countries and populations. Only a few cases of acne in the trunk area (back and chest) have been reported in literature. Although our clinical experience shows lower prevalence of truncal acne in comparison with facial acne, a community based study is needed to support this experience.

Methods: A total number of 1001 high school students, selected randomly from 5 out of 20 education-ministry subdivisions of Tehran, were included. In each area two high schools (one for boys and one for girls) with almost 100 students per high school were selected. Demographic data, family history and clinical findings were recorded in the questionnaires. Consensus Conference on Acne Classification was used for acne grading.

Results: One thousand one high school students, 503 girls and 498 boys ,were included. Prevalence of acne was 91.1% for face (95%CI: 83-99%), 93.4% in boys and 88.6% in girls. It was 53.4% for back (95%CI: 46-62.2%), 58.5% in boys and 36.9% in girls. Whereas for chest the prevalence was 36% (95%CI: 27-45%), 34.9% in boys and 36.9% in girls. Mean age of the students with truncal acne was 16.1 years where as 15.9 in others. This difference was significant (P<0.05). Positive family history was higher in students with truncal acne (P<0.001).

Conclusion: Truncal acne is less prevalent than facial acne. Acne on the back is significantly higher in boys than girls (P=0.002). Severe forms of acne in back may be more prevalent in boys. Positive family history can increase the risk of truncal acne.


The effects of Isotretinoin on serum levels of creatine phosphokinase and musculoskeletal symptoms in patients with acne vulgaris
Azizzadeh M, Yahyaee M, Ghorbani R,
Volume 69, Issue 5 (8-2011)
Abstract

Background: Acne vulgaris is a common dermatologic disease. Isotretinoin is one of the medications prescribed in severe cases of acne. Despite its high efficacy, isotretinoin use for acne is associated with some side effects. This study was done to evaluate the effects of isotretinoin on serum levels of creatine phosphokinase (CPK) and musculoskeletal symptoms in patients with acne vulgaris.

Methods: This study was done on forty 15- to 30-year-old patients with moderate to severe acne vulgaris recruited from Semnan dermatology clinics in 2010. The participants were all candidates for isotretinoin therapy. Serum CPK levels and musculoskeletal physical exam were checked before the treatment and every 2 months for 6 months. Isotretinoin was prescribed 0.5-1 mg/kg/body weight and continued throughout the study period with the same dosage.

Results: Thirty-three (82.5%) patients were female. The mean (±Standard Deviation) age of the participants was 22.3±3.4 years. The mean serum CPK levels increased significantly, (P< 0.05), 2, 4 and 6 months after the treatment, but they remained below the upper limit of normal range (45-160 IU/L), except in an 18-year old patient, which it was 162 IU/L. Moreover, they did not exhibit noticeable musculoskeletal symptoms. Musculoskeletal symptoms, such as mild myalgia, were reported in 10% of the patients but they were relieved gradually.

Conclusion: It seems that the increase in serum levels of CPK, with or without musculoskeletal symptoms, in patients who are on isotretinoin, is a benign phenomenon. Therefore, we do not recommend measurement of CPK levels in patients with mild myalgia.


Omeprazole versus doxycycline combination therapy with topical erythromycin the treatment of acne vulgaris: a randomized clinical trial
Fariba Jaffary , Mohammad Ali Nilforoushzadeh , Hanieh Sharifian Koupaiee , Gita Faghihi , Seyed Mohsen Hosseini , Fateme Sokhanvari , Nazli Ansari , Giti Sadeghian ,
Volume 75, Issue 1 (4-2017)
Abstract

Background: Acne vulgaris is self-limiting, multifactorial disease involving sebaceous glands. Omeprazole is a proton pump inhibitor with in vitro antibacterial effects against staphylococcus aureus and anti-androgen that can be potential treatment of acne vulgaris. This study was designed to evaluate the efficacy of oral omeprazole and erythromycin 4% compared to doxycycline combination therapy in the treatment of acne vulgaris.

Methods: In this clinical trial study, patients with moderate acne were referred to Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Science, Iran, during August 2014 until November 2015 and were randomized into two groups receiving topical erythromycin 4% plus omeprazole (34 patients) or doxycycline (35 patients) for 3 months. Moderate acne, lack of sensitivity to proton pump inhibitors, lack of warfarin, phenytoin, diazepam consumption, lack of active liver or kidney disease, being older than 12 years, were considered as inclusion criteria. Pregnant or lactating patients, patients with drug allergy history, patients taking oral contraceptives, acne topical medications (including retinoids) or systemic treatment within 30 days of study, patients with oligomenorrhea, hirsutism, acne conglobata, acne fulminant or body acne alone were excluded from the study. All patients were tested for Helicobacter pylori test at the beginning of the study.

Results: Both inflammatory and non-inflammatory lesions decreased in both groups with negative correlation with age (P< 0.05). There was no significant correlation between positive Helicobacter pylori test and inflammatory or non-inflammatory lesion reduction (P= 0.794, P= 0.514). Also, patient satisfaction and rate of total drug side effects was not different between two treatment groups. Rate of skin reactions was 20.58% in omeprazole treated group and 11.42% in doxycycline group. For side effects, other than skin it was 2.94% versus 14.28% respectively.

Conclusion: Omeprazole could be suggested as an alternative for doxycycline in the treatment of patients with moderate acne vulgaris especially in non-inflammatory lesions.

Comparing the efficacy of topical bepacto (dexpanthanol) versus intra muscular bepacto injection in treating mild to moderate acne: a split-face controlled trial
Mohammad Darayesh,
Volume 83, Issue 2 (5-2025)
Abstract
Background: Acne is a common adolescent skin disorder presenting with papules, pustules, and cysts on the face, chest, and back, which may persist into adulthood with varying severity. Dexpanthanol (bepacto) is an effective treatment for acne, administered both topically and intramuscularly. This study aimed to compare the efficacy of topical bepacto ointment versus intramuscular bepacto injections for mild to moderate acne.
Methods: This study was a randomized, controlled, split-face clinical trial. Patients were randomly divided into two groups: one receiving weekly intramuscular bepacto ampoule injections and the other applying topical bepacto ointment twice daily. The treatment protocol consisted of an initial one-month phase followed by a two-month continuation phase. Following acne diagnosis, patients were classified into three severity categories (mild, moderate and severe) according to Lehman's criteria. Data collection instruments for this study included a demographic information questionnaire and the Acne-QOL (Acne Quality of Life) questionnaire.
Results: The Mann-Whitney U test results indicated no statistically significant differences in quality-of-life outcomes between the topical and intramuscular treatment groups (P>0.05). Subsequent Friedman test analysis revealed distinct treatment response patterns: among 18-24-year-old patients with mild baseline acne severity, both treatment groups maintained mild severity at 2-week and 4-week follow-ups, with significant improvement achieved by week six. However, in moderate acne cases within the same age group, the topical treatment group showed progressive improvement - maintaining moderate severity at two weeks, progressing to mild by four weeks, and achieving complete resolution by week six. In contrast, the intramuscular group with moderate acne demonstrated persistent moderate severity at both 2-week and 4-week follow-ups, with only partial improvement to mild severity by week 6 and no complete resolution observed during the study period. These findings suggest that while both administration routes similarly affected quality of life measures, topical dexpanthanol demonstrated superior efficacy and faster response times, particularly in cases of moderate acne severity among young adult patients.
Conclusion: Intramuscular dexpanthanol may optimize treatment initiation timing and reduce costs in mild-to-moderate acne management.

Page 1 from 1     

© 2026 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb